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The National Health Service (NHS) Health Check programme was introduced in 2009 in
England to systematically assess all adults in midlife for cardiovascular disease risk factors.
However, its current benefit and impact on health inequalities are unknown. It is also unclear
whether feasible changes in how it is delivered could result in increased benefits. It is one of
the first such programmes in the world. We sought to estimate the health benefits and effect
on inequalities of the current NHS Health Check programme and the impact of making feasi-
ble changes to its implementation.
Methods and findings
We developed a microsimulation model to estimate the health benefits (incident ischaemic
heart disease, stroke, dementia, and lung cancer) of the NHS Health Check programme in
England. We simulated a population of adults in England aged 40–45 years and followed
until age 100 years, using data from the Health Survey of England (2009–2012) and the
English Longitudinal Study of Aging (1998–2012), to simulate changes in risk factors for
simulated individuals over time. We used recent programme data to describe uptake of
NHS Health Checks and of 4 associated interventions (statin medication, antihypertensive
medication, smoking cessation, and weight management). Estimates of treatment efficacy
and adherence were based on trial data. We estimated the benefits of the current NHS
Health Check programme compared to a healthcare system without systematic health
checks. This counterfactual scenario models the detection and treatment of risk factors that
occur within ‘routine’ primary care. We also explored the impact of making feasible changes
to implementation of the programme concerning eligibility, uptake of NHS Health Checks,
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and uptake of treatments offered through the programme. We estimate that the NHS Health
Check programme prevents 390 (95% credible interval 290 to 500) premature deaths before
80 years of age and results in an additional 1,370 (95% credible interval 1,100 to 1,690) peo-
ple being free of disease (ischaemic heart disease, stroke, dementia, and lung cancer) at
age 80 years per million people aged 40–45 years at baseline. Over the life of the cohort
(i.e., followed from 40–45 years to 100 years), the changes result in an additional 10,000
(95% credible interval 8,200 to 13,000) quality-adjusted life years (QALYs) and an additional
9,000 (6,900 to 11,300) years of life. This equates to approximately 300 fewer premature
deaths and 1,000 more people living free of these diseases each year in England. We esti-
mate that the current programme is increasing QALYs by 3.8 days (95% credible interval
3.0–4.7) per head of population and increasing survival by 3.3 days (2.5–4.1) per head of
population over the 60 years of follow-up. The current programme has a greater absolute
impact on health for those living in the most deprived areas compared to those living in the
least deprived areas (4.4 [2.7–6.5] days of additional quality-adjusted life per head of popu-
lation versus 2.8 [1.7–4.0] days; 5.1 [3.4–7.1] additional days lived per head of population
versus 3.3 [2.1–4.5] days). Making feasible changes to the delivery of the existing pro-
gramme could result in a sizable increase in the benefit. For example, a strategy that com-
bines extending eligibility to those with preexisting hypertension, extending the upper age of
eligibility to 79 years, increasing uptake of health checks by 30%, and increasing treatment
rates 2.5-fold amongst eligible patients (i.e., ‘maximum potential’ scenario) results in at least
a 3-fold increase in benefits compared to the current programme (1,360 premature deaths
versus 390; 5,100 people free of 1 of the 4 diseases versus 1,370; 37,000 additional QALYs
versus 10,000; 33,000 additional years of life versus 9,000). Ensuring those who are as-
sessed and eligible for statins receive statins is a particularly important strategy to increase
benefits. Estimates of overall benefit are based on current incidence and management, and
future declines in disease incidence or improvements in treatment could alter the actual ben-
efits observed in the long run. We have focused on the cardiovascular element of the NHS
Health Check programme. Some important noncardiovascular health outcomes (e.g.,
chronic obstructive pulmonary disease [COPD] prevention from smoking cessation and can-
cer prevention from weight loss) and other parts of the programme (e.g., brief interventions
to reduce harmful alcohol consumption) have not been modelled.
Conclusions
Our model indicates that the current NHS Health Check programme is contributing to
improvements in health and reducing health inequalities. Feasible changes in the organisa-
tion of the programme could result in more than a 3-fold increase in health benefits.
Author summary
Why was this study done?
• The National Health Service (NHS) Health Check programme is one of the first such
programmes in the world, and there is uncertainty about the impact of the programme
on health outcomes and inequalities.
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• The programme is evolving, although there have been no estimates of the impact of pos-
sible changes in the way that the programme is delivered on health outcomes or
inequalities.
What did the researchers do and find?
• We developed a longitudinal microsimulation model to simulate the NHS Health Check
programme and its impact on health, using epidemiological data for England and per-
formance data for the programme.
• We estimated that the current NHS Health Check programme is preventing approxi-
mately 300 premature deaths (before 80 years) and resulting in an additional 1,000 peo-
ple at age 80 years being free of cardiovascular diseases, dementia, and lung cancer each
year in England. If risk of cardiovascular disease continues to decline, then these bene-
fits will be attenuated by as much as a half.
• The benefits were greatest for people living in more deprived areas, and thus, the pro-
gramme as a whole is reducing health inequalities.
• Making feasible changes to the delivery of the existing programme is likely to result in
valuable improvements in health. For example, a strategy that combines extending eligi-
bility to those with preexisting hypertension, extending the upper age of eligibility to 79
years, increasing uptake of health checks by 30%, and increasing treatment rates
amongst eligible patients 2.5-fold (i.e., ‘maximum potential’ scenario) could result in at
least a 3-fold increase in benefits compared to the current programme.
What do these finding mean?
• The estimates of overall benefit are broadly in line with an estimate of likely benefit
made prior to the programme’s introduction, which provides reassurance that the pro-
gramme is meeting those expectations.
• The current practice of ensuring a higher attendance amongst people living in more
deprived areas appears to be reducing health inequalities.
• There appears to be considerable scope to improve the health benefit of the programme
by making feasible changes to its delivery, notably by ensuring those who are assessed
and eligible for treatments receive appropriate treatment. Focusing on inviting previous
nonattenders and widening the eligibility criteria to include those with an existing diag-
nosis of hypertension could also make a valuable contribution to increasing the health
benefits of the programme.
Introduction
The prevention of cardiovascular disease remains an important priority in the United King-
dom and elsewhere [1–4]. Cardiovascular disease accounts for around a quarter of all deaths
and costs around £15 billion annually in the UK [5]. While there are a set of well-established
actions to prevent cardiovascular disease, the uptake of these preventive interventions is sub-
optimal [6].
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To address this, structured vascular risk assessment for adults aged 40–74 years without
preexisting diabetes or cardiovascular disease (‘health checks’) was introduced in England in
2009 [7]. The programme sought to systematically identify individuals at risk of cardiovascular
disease through a structured risk assessment and an offer of appropriate treatment, either
pharmacological or behavioural. Now termed the National Health Service (NHS) Health
Check programme, it consists of a defined set of interventions. While other components have
been added over time, notably concerning alcohol, it retains a major focus on cardiovascular
disease prevention [8]. The programme has been criticised for lacking evidence of benefit [9],
and the overall health benefit it offers is unclear. While there have been trials of a ‘general
health check’ in the past, many of these studies are old, with some pre-dating the introduction
of more effective treatments like statins, and few, if any, of the interventions are comparable to
the NHS Health Check programme [10–12].
Published evaluations of the current programme estimate benefit in terms of changes in
cardiovascular risk factors (e.g., blood pressure), but these studies are prone to selection bias
and do not estimate changes in ‘hard’ health outcomes [13,14]. Previous modelling studies
have estimated the health benefit of a vascular check programme in England or the UK. One
prior to the programme’s introduction sought to explicitly model the NHS Health Check pro-
gramme and was based on an estimate of likely programme performance [7]. A second com-
pared a universal (vascular) screening programme (based in part on the NHS Health Check
programme) with concentrated screening and other population approaches to cardiovascular
disease prevention [15]. The third study compared 7 different models for the delivery of a vas-
cular ‘health check’ programme across 6 different European countries [16]. Whilst the vascular
check programmes modelled in the latter 2 studies shared similarities with the NHS Health
Check programme, neither explicitly modelled the NHS Health Check programme. None of
these modelling studies make use of the more detailed emerging empirical data that character-
ise uptake by sociodemographic characteristics or the full range of data available on pro-
gramme performance (e.g., referral to smoking cessation and weight management services)
[13].
Despite concerns about overall benefit [9], the programme remains in place, is legally man-
dated as a universal programme [17], receives high-level political support [18,19], and is per-
ceived favourably by patients [20,21]. Thus, the programme is likely to continue. A key focus is
whether and how the existing programme could be more effective or (further) reduce health
inequalities. Whilst there have been local evaluations of different approaches to programme
delivery, we are not aware of any studies that have quantified the health impact and/or the
effect on inequalities of making systemic changes to the programme’s delivery—for example,
changing eligibility criteria, increasing attendance, or increasing uptake of treatments offered
through the programme. Given that the programme is now established, it is an opportune
time to review how the programme might evolve or change in order to improve impact.
We sought to address 2 questions. First, what is the health benefit and effect on health
equity of the NHS Health Check programme as it is currently delivered in England? Second,
we sought to understand the health benefits (or losses) that might accrue from making changes
to the existing programme, considering eligibility criteria (widening or reducing eligibility);
increasing the uptake of the programme (either generically or amongst high-risk groups); and
improving uptake of treatments offered through the programme.
Methods
We developed a microsimulation model to assess the effect of, and modifications to, the car-
diovascular components of the NHS Health Check programme. The model consists of 2
The current and potential health benefits of the NHS Health Check programme
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modules (Fig 1). The first module (‘population and health’) describes the cardiovascular risk
factors, disease status, and mortality of the population over time. The second module (‘Health
Check’) simulates the different parts of the NHS Health Check: eligibility and attendance,
assessment for treatment, and the effect of treatment. Further technical information on the
methods are given as supplementary material (S1 Text), and the data inputs are summarised in
Table 1.
Population and health module
We simulated a closed cohort of 200,000 individuals aged 40–45 years representative of the
English population, by sampling individuals from the Health Survey for England 2009–2012 to
match the population structure (by gender and ethnicity) in the 2011 census [22]. Each indi-
vidual had a set of demographic characteristics (age, sex, ethnicity, deprivation, and education)
and a set of cardiovascular risk factors (blood pressure, smoking status, serum cholesterol, and
body mass index). We modelled annual change in risk factors using the English Longitudinal
Study of Aging (ELSA) (1998–2012) [23], which contains individual data on changes in cardio-
vascular risk factors over time and which (mostly) preceded the introduction of health checks.
Changes in risk factors were estimated by matching each individual in our simulated popula-
tion to one in the ELSA cohort with similar characteristics, with individuals being rematched
as their risk factors changed. This nonparametric approach allowed us to generate trajectories
that produced realistic results at the population level while also capturing between-individual
heterogeneity.
Diseases. We estimated incidence and case fatality by age (year increments) and sex for 4
diseases: lung cancer, ischaemic heart disease, stroke, and dementia. We used QRisk2 to
Fig 1. Outline of the microsimulation model.
https://doi.org/10.1371/journal.pmed.1002517.g001
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Table 1. Summary of data inputs.
Part of model Parameter Data source/assumption
Population Sociodemographic characteristics Health Survey for England 2009–2012 [31].
Health risk factors at baseline Health Survey for England 2009–2012 [31].
Change in risk factors over time English Longitudinal Study of Ageing (ELSA) 1998–2012 [23].
Disease Epidemiology Ischaemic heart disease (IHD) and stroke Individual 10-year risk of cardiovascular disease was calculated using the QRisk2
score [45]. The 10-year risk was converted to annual risk based on routine data
processed using DisMod. The likelihood of a new cardiovascular disease (CVD)
event being a stroke or IHD was determined by age- and sex-specific estimates of
incidence.
Estimates of case fatality were derived from routine data processed using DisMod
with further recalibration to account for raised mortality in the first year after
diagnosis or presentation (i.e., myocardial infarction: 32% for men and 30% for
women [34]; stroke: 7% for men and 5% for women aged under 80 years, 24% for
men and 17% for women aged over 80 years) [20]. We also assumed for men and
women that 58% and 44%, respectively, of IHD new presentations or diagnoses
presented as a myocardial infarction [33] and that 60% of stroke presentations
(QRisk2 includes both full strokes and transient ischaemic attacks) were a full stroke
rather than a transient ischaemic attack.
Routine data sources included the following: mortality statistics for England and
Wales [27], the Health Survey for England (prevalence) [31], estimates on case
fatality for IHD in England from linked mortality and hospital record data [46], and
estimates on case fatality rates for stroke based on primary care records in the UK
[47].
Dementia Individual 20-year risk of dementia was calculated using the cardiovascular risk
factors, aging, and incidence of dementia risk (CAIDE) score [48]. The 20-year risk
was converted to annual risk based on routine data processed using DisMod.
Estimates of case fatality were derived from routine data processed using DisMod.
Routine data sources included the following: the Cognitive Function and Aging
Study II in England (incidence) [29] and a published audit of primary care records
in the UK (relative risk of mortality) [30].
Lung cancer Annual estimates of incidence were based on routine data sources processed using
DisMod. Lung cancer cases were attributed to smoking or not, based on published
estimates of the proportion of lung cancer cases attributable to smoking in the UK
[36].
Routine data sources included the following: mortality statistics for England and
Wales [27] and cancer registry data for England (incidence) [26].
National Health Service (NHS)
Health Check programme
Proportion of eligible population offered a health check 19.7% per year, based on published evaluation [49].
Proportion of people offered a health check who attend Estimates of uptake based on published evaluations and likelihood of attendance
varied by age, sex, ethnicity, deprivation, smoking status, and QRisk2 score
[13,14,50].
Proportion of people getting a health check who are not
eligible on the basis of a chronic condition




Proportion of smokers at health check who are referred
to smoking cessation therapy
3.6% (95% CrI 3.3% to 3.9%), assuming 6.8% of smokers (2,571/37,808) who had a
health check were referred to smoking cessation, compared to 3.2% (9,944/310,034)
of smokers who do not have a health check based on published programme
evaluation [13].
Proportion of obese people (BMI  30) at health check
who are referred to weight management interventions
27.5% (95% CrI 26.9% to 28.1%), assuming 38.7% (12,430/32,133) of obese people
who had a health check were referred to weight management, compared to 11.2%
(4,441/39,774) of obese people who did not have a health check [13].
Only considers weight management, not the additional 31.1% of obese people who
were referred to exercise, a group which is assumed to overlap substantially.
Proportion who receive statins QRisk2 < 20%: 2.05% (95% CrI 1.97 to 2.13) additional statin prescriptions in
health check attenders versus nonattenders.
QRisk2  20%: 14.23% (95% CrI 13.71 to 14.76) additional statin prescriptions in
health check attenders versus nonattenders.
Based on published evaluation [13].
Proportion of people with high blood pressure who
receive antihypertensives
QRisk2 < 20%: 1.54% (95% CrI 1.46 to 1.62) additional antihypertensive
prescriptions in health check attenders versus nonattenders.
QRisk2  20%: 2.48% (95% CrI 2.05 to 2.90) additional antihypertensive
prescriptions in health check attenders versus nonattenders.
Only individuals with hypertension at health check (defined as systolic blood
pressure greater than 140 mmHg) were assumed to get antihypertensive treatment
in either case.
Based on published evaluation [13].
(Continued)
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estimate risk of incident cardiovascular disease for each simulated individual based on socio-
demographic and cardiovascular risk factors and the CAIDE score to estimate dementia inci-
dence. These tools provide estimates of risk over a 10- and 20-year period, respectively, which
were then converted to annual estimates of risk based on average estimates of population inci-
dence estimated using DisMod II v1.05 [24] and routine data [25–31]. DisMod was used to
generate annual estimates of incidence and case fatality from 2 or more estimates of routine
data (e.g., prevalence and mortality).
QRisk2 estimates the risk of incident (first) diagnosis of cardiovascular disease (ischaemic
heart disease, stroke, or TIA). New cardiovascular events were assigned at random to be either
ischaemic heart disease or a stroke, reflecting the relative proportions of these events by age. In
doing this, we assumed that the ratio of strokes to TIAs was 60:40 [32].
We assumed that 58% of new diagnoses of ischaemic heart disease for men and 44% for
women were an acute myocardial infarction [33]. We further assumed that a proportion of
acute events (32% for men and 33% for women for acute myocardial infarction; 7% for men
Table 1. (Continued)
Part of model Parameter Data source/assumption
Adherence to treatment Smoking cessation We assumed that 100% of patients referred ‘adhere’ to treatment, as the treatment
effectiveness estimates include those who are nonadherent.
Weight management programme We assumed 50% attend at least one session, i.e., assuming a lower real-world take-
up rate than that in published trials of weight-loss interventions (e.g., 68% in
Weight Loss Referrals for Adults in Primary Care [WRAP] trial) [51].
We assumed a 95% CrI of 30% to 70%.
Statins 50% adherence to initial prescription (with a 95% CrI of 40% to 60%, from our
assumption), based on published estimates [52–54].
An additional 5% (95% CrI 3% to 7%) of people taking statins are assumed to stop
taking them each year (our assumption).
Antihypertension medication 55% adherence (with a 95% CrI of 45% to 65%, from our assumption), based on
published estimates [52,54,55].
An additional 5% (95% CrI 3% to 7%) of people on antihypertensives (AHTs) are
assumed to stop taking them each year (our assumption).
Treatment effectiveness Smoking cessation Based on an evaluation of an English smoking cessation service, we assumed that
14.6% (95% CrI 13.1% to 16.1%) of those who are referred have quit at 1 year [56].
Relapse after quitting is modelled using ELSA data.
Weight management effectiveness Based on a published audit of weight management services in the UK, we assumed a
mean BMI change of −1.5 kg/m2 by 1 year for everyone attending at least 1 session
[57]. Lost weight assumed to be regained over 5 years, with BMI changes of −1.5,
−0.9, −0.6, −0.3, and 0 at 1, 2, 3, 4, and 5 years after health check, respectively (our
assumption).
Statin effectiveness Based on a meta-analysis of trials of efficacy of statins on cholesterol, we assumed a
mean change of −1.22 (95% CrI −1.19 to −1.26) for men and −1.16 (95% CrI −1.10
to −1.23) for women in total cholesterol at 1 year [58] and a mean increase in high-
density lipoprotein (HDL) at 1 year of 0.04 (95% CrI 0.028 to 0.052) for men and
0.036 (95% CrI 0.012 to 0.060) for women ([58]).
Further adjustment was made to CVD risk for those on statins, reflecting published
data on the efficacy of statin treatment (which was not adequately captured by
changes in QRisk2 score) [58].
Antihypertensive medication effectiveness We assumed that those under 55 years used an angiotensin-converting-enzyme
(ACE) inhibitor and those aged 55 years and over used calcium channel blockers.
Based on a meta-analysis of efficacy of Ramipril on blood pressure, we assumed a
mean change of −6.29/−4.14 mmHg (95% CrI −9.26 to −3.32/−5.81 to −2.48) [59].
Based on a meta-analysis of the efficacy of a calcium channel blocker on blood
pressure, we assumed a mean change of −7.6/−3.1 mmHg (95% CrI −7.95 to −7.25/
−2.75 to −3.45) for men and −9.0/−3.5 mmHg (95% CrI −8.68 to −9.32/−3.18 to
−3.82) for women [60].
Published 95% confidence intervals have been used as estimates for 95% credible intervals.
https://doi.org/10.1371/journal.pmed.1002517.t001
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and 5% for women under the age of 80 years, and 24% and 17% for men and women aged 80
years and over) were fatal [34,35]. Making allowance for acute fatality, we recalibrated the
annual estimates of case fatality, from DisMod based on routine data sources, to account for
acute mortality, i.e., we modelled a higher fatality in the year of diagnosis or presentation.
Unadjusted estimates of case fatality by age and sex for dementia and lung cancer from Dis-
Mod were used.
For smoking, we calculated separate incidence rates for smokers and nonsmokers using
DisMod based on reported population attributable fractions [36].
Whilst dementia was not a focus in the original programme [7], it has subsequently been
included. Dementia shares many of the same risk factors as ischaemic heart disease and stroke,
and vascular pathology in the brain is associated with dementia [37–39]. It is thought that
dementia risk is modifiable and that recent reductions in incidence might be attributable to
better management of cardiovascular risk [29,40,41]. On this basis, dementia was included in
the model, although to date there is no evidence from randomised clinical trials showing that
dementia risk can be reduced.
Once an individual developed a disease, it was assumed that he or she had the disease for
life, adopting the appropriate mortality risk. Mortality from all other causes was estimated
using standard life tables [42], after adjusting for cause-specific mortality within the model.
The model proceeds in annual increments, with individuals followed until death or 100 years
of age.
At the beginning of the simulation, a proportion of the population (based on estimates
from DisMod) were assumed to have ischaemic heart disease or stroke. The probability of hav-
ing cardiovascular disease at baseline depended on the QRisk2 score at baseline. We assumed
that nobody had dementia or lung cancer at baseline.
Health check module
Simulated individuals were eligible for a health check based on their age and their disease sta-
tus (absence of diabetes, cardiovascular disease, and hypertension), reflecting current eligibility
criteria. We assumed that the annual probability of an eligible individual being offered a health
check was 0.197, based on national programme data [43]. Thus, on average, a person would be
offered a health check once every 5 years.
We assumed that the likelihood of attendance was determined by sociodemographic char-
acteristics (age, ethnicity, and area-level deprivation) and cardiovascular risk factors (smoking
status and QRisk2), based on programme data[13], and (in the absence of long-term data) we
assumed that past attendance did not affect future attendance. We also assumed that 5% of
ineligible individuals attended for an NHS Health Check, e.g., via a drop-in clinic in a
pharmacy.
We assumed that individuals could be offered 1 or more of 4 treatments: statins, antihyper-
tensives, smoking cessation, and weight management [44]. Assumptions regarding who got
treated, adherence to treatment, and the effect of treatment are summarised in Table 1. We
assumed no interaction between treatments.
For all individuals receiving statins, antihypertensives, or weight management, a counter-
factual trajectory for each risk factor, without treatment after an NHS Health Check, was simu-
lated using the ELSA data. A treatment trajectory was then estimated by adjusting the
counterfactual trajectory to represent the effect of treatment. For example, if a woman was
compliant with statin therapy (initiated because of a health check), her cholesterol level would
be 1.16 mmol/L lower than her background (or ‘counterfactual’) cholesterol. For individuals
who quit smoking after attending a smoking cessation programme, their risk of relapse and
The current and potential health benefits of the NHS Health Check programme
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future smoking status were estimated by matching to individuals in the ELSA dataset and
adjusting for published evidence on quitting and relapsing [61]. In all cases, we have effectively
modelled a decline in treatment effectiveness over time due either to reduced adherence or
relapse (see Table 1) such that the health benefits over time may appear to be less than expected
from trial data but should be more akin to the benefit attributable to the NHS Health Check
programme in the real world.
The simulation model was written in Python (version 2.7.6). The full source code is avail-
able under licence from a GitHub repository (https://github.com/chjackson/healthchecks).
Modelled health benefits
In all cases, the effect of changes in risk factors on health was modelled through the respective
disease risk scores for cardiovascular disease and dementia. For smoking, we estimated sepa-
rate incidence rates for smokers and nonsmokers, as described previously. Body mass index
was assumed to have a direct effect on QRisk2 score (rather than through changes in blood
pressure and cholesterol).
Model calibration and validation
We sought to identify the most suitable data for our model and focused on developing the
aspects of the model that are most important for the scenarios we sought to explore. During
the development of the model, we undertook a series of checks to ensure the model was accu-
rately simulating the health check process (i.e., attendance and treatment uptake) and outputs
(e.g., blood pressure and QRisk2) by comparing model outputs with empirical data. We also
compared trial data for blood pressure medication and statins with published trial data on
treatment efficacy. Changes in QRisk2 due to changes in serum cholesterol did not accurately
capture the reduction in risk for statin treatment reported in trials, as would be expected, as
statins reduce cardiovascular risk by other means (e.g., reducing inflammation) [62]. Conse-
quently, we made a further adjustment to cardiovascular disease (CVD) risk for people who
were started on a statin by calibrating the modelled reduction in CVD event rates over 5 years
achieved by statin so that it was equal to the value observed in trials [58]. To validate the popu-
lation and health module, we compared estimates of mortality for ischaemic heart disease and
stroke by sex—produced by this part of the model—with published estimates of mortality
based on death certification [25]. There was reasonably close agreement (S1 Data).
Scenarios
First, we compared the present NHS Health Check programme (assuming it continues to
operate in its present format) to a counterfactual in which no NHS Health Check programme
operated. Second, we explored different scenarios for how the NHS Health Check programme
could evolve in the future, considering 3 areas: eligibility criteria, uptake of the programme,
and treatment.
We considered 4 scenarios in which the eligibility criteria would change: (1) extending the
programme to invite those who already have a diagnosis of hypertension, (2) increasing the
age at which individuals are first invited for a health check from 40 years to 50 years of age, (3)
increasing the upper age at which individuals may be invited to attend the programme from
74 years to 79 years, and (4) changing both the upper and lower age criteria, such that persons
aged 50–79 years would be invited.
We considered 5 scenarios in which the likelihood of attendance was increased by 30%: (1)
for everyone invited, (2) for people living in the most deprived areas (bottom quintile group),
The current and potential health benefits of the NHS Health Check programme
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(3) for smokers, (4) for those at high cardiovascular risk (QRisk2 > 20%), and (5) for nonat-
tenders (people who did not attend in the past 5-year cycle).
We considered 5 scenarios in which the likelihood of receiving treatment amongst those eli-
gible at assessment was increased 2.5-fold for statins alone, antihypertensives alone, smoking
cessation alone, weight management alone, and all treatments. The value of 2.5 was selected in
light of evidence from Tower Hamlets, London, indicating that the proportion of high-risk
(QRisk2 > 20%) health check attenders additionally prescribed statins was around 36%,
approximately 2.5 times higher than the national figure of 14% [63]. Whilst it is unclear what
the maximum feasible uptake of different treatments is, we have modelled the same relative
increase for all treatments and note that programme data suggest that such increases appear,
on paper, to be feasible.
Finally, to demonstrate the combined benefit of increasing uptake and improving delivery
of health checks, we simulated the effect of simultaneously widening eligibility to include those
with a diagnosis of hypertension, increasing attendance by 30% for everyone and increasing all
treatments by 2.5-fold, which we will term a ‘maximum potential’ scenario.
Outcomes
Primary outcomes are total incident cases prevented (by age 80 years), premature deaths pre-
vented (<80 years), change in quality-adjusted life years (QALYs), and change in survival. We
also report incident events prevented by age 100 years (as well as providing a breakdown by
disease category) and deaths prevented before 75 years of age. We provide estimates of the
total additional quality-adjusted years lived and years lived for the studied cohort of 1,000,000
people and estimates per head of population. We use the latter metric as the primary means to
describe the effect of health inequalities, as these measures make allowance for different popu-
lation sizes.
Standard EQ-5D disutility weights for age, deprivation, and disease status were used to esti-
mate QALYs [64].
To provide a comparison with other published estimates that describe the number of events
avoided in England each year, we multiply our estimates for events avoided over the life of the
cohort by 0.73 (there are approximately 730,000 adults aged 40 in any given year in England).
This assumes the benefits observed for the current population in any given year are compara-
ble to the benefits that the cohort (aged 40–45 years) experience longitudinally.
We also provide estimates for those living in the most and least deprived areas (expressed
per head of population to standardise for differences in population size). Each simulated indi-
vidual adopted the quintile group of the sampled individual from the Health Survey for
England (based on the Index of Multiple Deprivation for the area of residence).
Uncertainty analyses
We used probabilistic methods to account for uncertainty in parameters entered into the
model. We assigned a probability distribution, rather than a fixed value, for each input param-
eter. We then ran our model 100 times, each time sampling each parameter from its stated dis-
tribution. This yielded 100 output values, from which we calculated a mean and 95% credible
intervals. The number of samples was chosen such that the sampling error in mean outcomes
over individuals (due to simulating a finite number of individuals) was small (<5% of that due
to parametric uncertainty). In each run, we simulated 200,000 individuals, effectively sampling
20 million individuals for each modelled scenario.
We also undertook ‘value of information analyses’ to identify which sources of parametric
uncertainty were contributing the most to uncertainty in the results. These are calculated by
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estimating the standard deviation for the result if the exact value of the parameter of interest
were to be learnt. This can be compared to the width of the original 95% credible interval to
describe the potential value of obtaining perfect information on that parameter. All parameters
with uncertainty or credible intervals were considered. We repeated the ‘value of information
analysis’ for 2 of the scenarios: our first scenario (comparing the NHS Health Check pro-
gramme to a counterfactual in which no programme operated) and the ‘maximum potential’
scenario.
Sensitivity analyses
We also undertook the following sensitivity analyses:
1. Future attendance was independent of past attendance
The model assumes that attendance at a health check is independent of past attendance
record. Given the programme has been in existence for less than 10 years, there is limited
long-term data to assess the extent to which past attendance predicts future attendance.
However, we note that for similar programmes (i.e., screening programmes) past atten-
dance can be a predictor of future attendance [65–67]. We thus modelled the current pro-
gramme under the assumption that likelihood of attendance was greater (average of 70%
per 5-year cycle) if somebody attended after his or her most recent offer of a health check
and less if he or she did not (average 30%). We further tested the effect of this assumption
on the scenario concerned with increasing invitations to nonattenders.
2. Future changes in CVD incidence and fatality
The model assumes that present incidence of and case fatality from CVD continue. How-
ever, age-standardised mortality for ischaemic heart disease and stroke has fallen over the
past 50 years [68], and while there is uncertainty about the nature of future trends, particu-
larly in light of the rising prevalence of obesity and diabetes[69], it seems likely that these
trends will continue at least in the short to medium term. We assumed that the recently
observed trends would continue for the next 20 years before plateauing. We assumed that
the incidence of ischaemic heart disease (IHD) would fall by 4.8% for men and 4.5% for
women per year [34] and that stroke incidence would fall by 4.0% per year [47]. We
assumed that the case fatality for IHD would fall by 3.6% per year [34] and that the case
fatality for stroke would fall by 6.0% per year [35]. We did not model declines for a longer
period of time as the observed trends were for a short time period and there is considerable
uncertainty about long-term trends.
3. Uncertainty in population cardiovascular risk (at baseline)
To understand the extent to which our estimates would change if the model’s estimate of
cardiovascular risk in the cohort was too high or too low (i.e., reflect uncertainty in our esti-
mate of average risk in the population), we reran our model by multiplying the QRisk2
score by a value chosen from a log-normal distribution with 95% quantiles of 0.8 and 1.2.
The value was applied to each simulated individual in any given run of the model (with dif-
ferent values drawn from the distribution being applied to different runs).
Results
The baseline characteristics of the population aged 40–45 years are shown in Table 2. In the
absence of the NHS Health Check programme, we estimate that per million people aged 40–45
years at baseline in the 60 years of follow-up, there will be 355,000 diagnoses of IHD, 184,000
The current and potential health benefits of the NHS Health Check programme
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Table 2. Baseline characteristics of the whole population aged 40–45 years and those who go on to participate in
the health check programme.
Everyone aged 40–
45 years
People eligible for a health check
at least once (85%)
People who go on to attend at least
1 health check (77%)
Gender
Male 50.4% 51.1% 51.6%
Female 49.6% 48.9% 48.4%
Ethnicity
White 86.1% 86.2% 86.2%
Indian 2.5% 2.6% 2.7%
Pakistani 2.4% 2.4% 2.4%
Caribbean 1.6% 1.5% 1.5%
African 2.2% 2.2% 2.1%
Other 5.1% 5.1% 5.1%
Deprivation
1 (least deprived) 22.1% 23.5% 23.0%
2 22.9% 22.3% 22.2%
3 21.3% 22.6% 22.2%
4 19.8% 19.3% 19.4%





7–9 years 45.7% 45.1% 45.2%
6 years 9.4% 9.0% 9.1%
QRisk2 2.9 (1.1 to 3.8) 2.5 (1.0 to 3.3) 2.6 (1.1 to 3.4)
QRisk2 >20 0.4% 0.2% 0.2%





120.7 (111.5 to 128) 120.9 (112.5 to 128.5)
Diastolic blood
pressure







Cholesterol 5.5 (4.8 to 6.1) 5.5 (4.8 to 6.1) 5.5 (4.8 to 6.1)
TC/HDL 4.0 (3.0 to 4.9) 4.0 (2.9 to 4.8) 4.0 (3.0 to 4.8)
BMI (kg/m2) 27.5 (24.2 to 30.2) 27.1 (23.9 to 29.6) 27.1 (24.2 to 29.8)
Obese 27.1% 23.0% 23.6%
HbA1c 5.6 (5.3 to 5.7) 5.5 (5.3 to 5.7) 5.5 (5.3 to 5.7)
HbA1c >6.5% 3.4% 4.0% 4.4%
Diabetes 3.3% 0.0% 1.0%
Smoking
Never 52.6% 52.8% 53.3%
Ex 22.8% 22% 22.4%
Current 24.6% 25.2% 24.3%
Abbreviations: HbA1c, haemoglobin A1c; HDL, high-density lipoprotein; TC, total cholesterol. Mean and
interquartile range are given for continuous variables. Deprivation quintile groups are based on the Index of Multiple
Deprivation for the area of residence. QRisk2 is the 10-year risk of cardiovascular disease [45].
https://doi.org/10.1371/journal.pmed.1002517.t002
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diagnoses of stroke, 147,000 diagnoses of dementia, 148,000 diagnoses of lung cancer, and
405,000 premature (<80 years) deaths.
Current programme
At some point during their 35-year period of potential eligibility, we estimate that 85% of the
cohort will be eligible for and 80% will attend for at least 1 health check (Table 3). Whilst the
majority (81% of the population) will be eligible for treatment at some point, only a minority
(27% of the population) are offered treatments through the NHS Health Check programme.
The most common treatment offered is weight management.
We estimate that the NHS Health Check programme prevents 390 (95% credible interval
[CrI] 290 to 500) premature deaths before 80 years of age and results in an additional 1,370
(95% CrI 1,100 to 1,690) people being free of disease (IHD, stroke, dementia, and lung cancer)
at age 80 years per million people aged 40–45 years at baseline.
Over the life of the cohort (i.e., followed from 40–45 years to 100 years), we estimate the
changes result in an additional 10,000 (95% CrI 8,200 to 13,000) QALYs and an additional
9,000 (6,900 to 11,300) years of life. This is equivalent to 3.8 (3.0 to 4.7) days of quality-adjusted
life per head of population and an increase in survival of 3.3 (2.5 to 4.1) days per head of popu-
lation. The increase in quality-adjusted life (3.8 days) is greater than the increase in survival
(3.3 days), i.e., the intervention results in compression of morbidity.
Assuming there are 730,000 people aged 40 years in England each year, this would equate
to approximately 300 fewer premature deaths before 80 years of age, 1,000 more people living
free of CVD, dementia, and lung cancer at age 80 years, 7,500 additional QALYs, and 6,600
extra years of life each year in England.
Changing eligibility criteria
The effect of making changes to the eligibility criteria is shown in Table 4. All the estimates for
health impacts (cases prevented, deaths prevented, QALYs, and survival) are changes relative
to the current NHS Health Check programme. To estimate changes in these outcomes relative
to a counterfactual with no NHS Health Check programme, these values should be added to
the corresponding values in Table 3.
Options associated with improvements in population health were opening the programme
to people with a diagnosis of hypertension and extending the upper age of cutoff to 79 years.
Increasing the starting age for eligibility from 40 years to 50 years was associated with a reduc-
tion in population health. A hybrid approach, raising the starting age and raising the upper age
cutoff, was also associated with an improvement in population health (the loss from increasing
the starting age being offset by the gain from increasing the upper age cutoff).
Increasing attendance
Increasing attendance is associated with improvements in indices of population health
(Table 5). Increasing attendance for everyone (by 30%) results in the greatest improvements in
population health, although selective approaches (e.g., increasing attendance amongst those at
high risk of CVD by 30% or increasing the likelihood of invitation to those who did not attend
in the past 5-year cycle) may yield relatively large gains in population health for fewer addi-
tional health check appointments.
Increasing uptake by 30% amongst those living in the most deprived areas (bottom fifth) is
an effective means to reduce inequalities, although it is associated with relatively small gains in
measures of average population health.
The current and potential health benefits of the NHS Health Check programme
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Table 3. Summary of process measures and outcomes for the present National Health Service (NHS) health check programme.
Eligibility and uptake (for whole population)
Eligible for an NHS Health Check at any time (%) 85.1
Have one or more NHS Health Checks (%) 79.7
Mean health checks (per person) 1.9
Treatment (as a proportion of the whole population)
Eligible for an NHS Health Check and any treatment (%) 81.0
Attended for an NHS Health Check and eligible for any treatment (%) 73.3
Offered any treatment (%) 26.6
Offered statins through an NHS Health Check (%) 8.5
Offered antihypertensives through an NHS Health Check (%) 3.3
Referrals for a weight loss programme through an NHS Health Check (%) 17.6
Referrals for smoking cessation services through an NHS Health Check (%) 1.2
Treated with statins through an NHS Health Check (%) 4.3
Treated with antihypertensives through an NHS Health Check (%) 1.8
Attended a weight loss programme after referral from an NHS Health Check (%) 10.0
Attended smoking cessation after referral from an NHS Health Check (%) 0.1
Cases prevented by age 80 (per million)
IHD 1,089 (817 to 1,367)
Stroke 525 (414 to 671)
Dementia 135 (72 to 190)
Lung cancer 90 (36 to 147)
Additional people living free of one of the diseases listed above at age 80 years 1,371 (1,101 to 1,685)
Cases prevented by age 100 (per million)
IHD 1,296 (898 to 1,730)
Stroke 679 (494 to 958)
Dementia 125 (32 to 222)
Lung cancer 175 (103 to 259)
Additional people living free of one of our diseases at age 100 years 1,235 (956 to 1,566)
Premature deaths prevented (per million)
<75 years 246 (182 to 331)
<80 years 386 (291 to 499)
Quality-adjusted life gained over 60 years of follow-up
Total (QALYs for whole population) 10,300 (8,170 to 12,900)
Days per head of population 3.8 (3.0 to 4.7)
Days per eligible person 4.3 (3.4 to 5.4)
Days per person screened at least once 4.7 (3.8 to 6)
Days per health check 2.0 (1.6 to 2.5)
Days per head (most deprived quintile group) 5.1 (3.4 to 7.1)
Days per head (least deprived quintile group) 3.3 (2.1 to 4.5)
Life gained over 60 years of follow-up
Total (years for whole population) 9,700 (6,880 to 11,300)
Days per head of population 3.3 (2.5 to 4.1)
Days per eligible person 3.7 (2.8 to 4.8)
Days per person screened at least once 4.1 (3.2 to 5.2)
Days per health check 1.7 (1.4 to 2.2)
Days per head (most deprived quintile group) 4.4 (2.7 to 6.5)
Days per head (least deprived quintile group) 2.8 (1.7 to 4.0)
Abbreviations: HC, an NHS Health Check; IHD, ischaemic heart disease. Deprivation quintile groups are based on the Index of Multiple Deprivation score for the area
of residence. Cases prevented are all cases prevented when following a cohort of 1 million adults aged 40–45 years until either 80 or 100 years of age. Premature deaths
prevented are all-cause deaths prevented before age 75 or 80 years, when following a cohort of 1 million adults aged 40–45 years until 80 years of age. Quality-adjusted
life gained and life gained are over the 60 years of follow-up, i.e., the remaining lifetime of the cohort. Estimates of 95% credible intervals (due to parameter uncertainty)
are shown in parentheses. The 95% credible intervals are the 2.5th and 97.5th percentile of all estimates from 100 simulations.
https://doi.org/10.1371/journal.pmed.1002517.t003
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Upper age of eligibility
79 years
Starting age (50 years) and upper
eligibility age (79 years)
Eligibility and uptake
Eligible for HC at any time (%) 92.5 79.7 85.1 79.8
Have one or more HCs (%) 85.3 76.8 79.8 77.2
Mean HCs per head of population 2.1 1.7 2.1 1.9
Treatment (proportion of whole population)
Eligible for HC and any treatment (%) 88.3 76.9 81.0 76.9
Attended HC and were eligible for any treatment
when attending (%)
79.0 71.5 74.5 72.9
Offered any treatment through HC (%) 29.6 25.1 29.5 28.2
Offered statins through HC (%) 9.4 8.0 10.7 10.3
Offered antihypertensives through HC (%) 3.7 3.0 3.8 3.5
Referred to a weight loss programme through HC
(%)
19.9 16.6 18.9 18
Referred to smoking cessation services through
HC (%)
1.3 1.1 1.3 1.1
Treated with statins through HC (%) 4.8 4.1 5.4 5.3
Treated with antihypertensives through HC (%) 2.0 1.6 2.1 1.9
Attended a weight loss programme after HC
referral (%)
11.3 9.4 10.9 10.3
Attended smoking cessation services after HC
referral (%)
0.1 0.1 0.1 0.1
Additional cases prevented by age 80 (per million)
IHD 162 (91 to 232) −38 (−81 to −4) 136 (93 to 184) 97 (40 to 160)
Stroke 76 (36 to 118) −19 (−49 to 5) 68 (30 to 111) 49 (−1 to 99)
Dementia 16 (−11 to 45) −13 (−36 to 8) 0 (−5 to 0) −13 (−36 to 8)
Lung cancer 12 (−5 to 30) −8 (−25 to 6) 5 (−1 to 16) −3 (−21 to 16)
Additional people living free of one of our
diseases at age 80 years
194 (114 to 264) −53 (−94 to −7) 185 (111 to 248) 133 (48 to 203)
Additional cases prevented by age 100 (per million)
IHD 179 (110 to 279) −36 (−76 to 0) 339 (226 to 442) 303 (198 to 411)
Stroke 88 (41 to 155) −17 (−52 to 8) 188 (108 to 272) 171 (90 to 253)
Dementia 13 (−21 to 42) −16 (−38 to 14) −25 (−45 to −4) −41 (−73 to 0)
Lung cancer 23 (3 to 51) −13 (−39 to 6) 16 (−3 to 39) 3 (−28 to 35)
Additional people living free of one of our
diseases at age 100 years
160 (89 to 219) −44 (−81 to −4) 330 (235 to 436) 286 (183 to 392)
Additional premature deaths prevented (per million)
<75 years 34 (9 to 65) −15 (−39 to 1) 0 (0 to 0) −15 (−39 to 1)
<80 years 57 (19 to 99) −18 (−44 to 5) 33 (9 to 68) 15 (−24 to 49)
Additional quality-adjusted life gained over the 60 years of follow-up
Total (QALYs for whole population) 1,400 (688 to 2,010) −604 (−1,090 to
−127)
1,480 (868 to 2,050) 876 (185 to 1,670)
days per head of population 0.5 (0.3 to 0.7) −0.2 (−0.4 to 0.0) 0.5 (0.3 to 0.7) 0.3 (0.1 to 0.6)
days per eligible person 0.6 (0.3 to 0.8) −0.2 (−0.4 to 0.0) 0.6 (0.4 to 0.9) 0.4 (0.1 to 0.8)
days per person screened at least once 0.6 (0.3 to 0.9) −0.2 (−0.4 to 0.0) 0.7 (0.4 to 0.9) 0.5 (0.2 to 0.9)
days per health check 0.0 (−0.1 to 0.2) 0.1 (0.0 to 0.2) 0.1 (0.0 to 0.2) 0.2 (0.0 to 0.3)
days per head (most deprived quintile group) 0.9 (0.2 to 1.7) −0.3 (−0.8 to 0.4) 0.5 (0.1 to 1) 0.2 (−0.5 to 1)
days per head (least deprived quintile group) 0.4 (0 to 0.8) −0.2 (−0.5 to 0.1) 0.6 (0.2 to 1) 0.4 (−0.2 to 0.9)
Additional life gained over the 60 years of follow-up
Total (years for whole population) 1,220 (577 to 1,860) −511(−29.5 to
−1,060)
1,320 (706 to 1,870) 813 (83.5 to 1,640)
(Continued)
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Increasing treatment
A 2.5-fold increase in the likelihood of starting treatment amongst those eligible was associated
with relatively large improvement in indices of population health (Table 6) compared to
increases in attendance or changes in eligibility criteria. The largest gains are seen for a
2.5-fold increase in statin treatment. Increasing all treatments 2.5-fold increases the health
benefits of the programme 2- to 3-fold (950 deaths versus 390; 3,400 people free of 1 of the 4
diseases versus 1,370; 25,000 additional QALYs versus 10,000; 22,000 additional years of life
versus 9,000). Increasing treatment rates is associated with compression of morbidity (the
increase in QALYs is greater than the increase in survival).
A strategy that combines extending eligibility to those with preexisting hypertension,
extending the upper age of eligibility to 79 years, increasing uptake by 30%, and increasing
treatment rates 2.5-fold among eligible patients (i.e., ‘maximum potential’ scenario) results in
at least a 3-fold increase in benefits compared to no programme (1,360 premature deaths ver-
sus 390; 5,100 people free of 1 of the 4 diseases versus 1,370; 37,000 additional QALYs versus
10,000; 33,000 additional years of life versus 9,000).
Effect on health equity
The current programme has a greater absolute impact on health for those living in the most
deprived areas compared to those living in the least deprived areas (gain in quality-adjusted
life of 5.1 days for those in the most deprived area versus 3.3 days for those in the least deprived
area; gain in life expectancy of 4.4 days versus 2.8 days, respectively).
We summarise our estimates on health equity and overall effectiveness in Fig 2. Most modi-
fications to the programme that are associated with an improvement in health equity are also
associated with an improvement in overall population health.
Value of information analyses
A value of information analysis that considered the different sources of parametric uncertainty







Upper age of eligibility
79 years
Starting age (50 years) and upper
eligibility age (79 years)
days per head of population 0.4 (0.2 to 0.7) −0.2 (−0.4 to 0.0) 0.5 (0.3 to 0.7) 0.3 (0.0 to 0.6)
days per eligible person 0.5 (0.2 to 0.7) −0.2 (−0.4 to 0.0) 0.6 (0.3 to 0.8) 0.4 (0.1 to 0.8)
days per person screened at least once 0.5 (0.2 to 0.8) −0.1 (−0.3 to 0.0) 0.6 (0.3 to 0.9) 0.5 (0.2 to 0.8)
days per health check 0.0 (−0.1 to 0.2) 0.1 (0.0 to 0.2) 0.1 (0.0 to 0.2) 0.1 (0.0 to 0.3)
days per head (most deprived quintile group) 0.8 (0.1 to 1.7) −0.2 (−0.8 to 0.4) 0.5 (0.0 to 1.0) 0.2 (−0.5 to 1.1)
days per head (least deprived quintile group) 0.3 (0.0 to 0.8) −0.2 (−0.5 to 0.1) 0.5 (0.2 to 1.0) 0.4 (−0.2 to 0.8)
Abbreviations: HC, an NHS Health Check; IHD, ischaemic heart disease; QALY, quality-adjusted life year. Deprivation quintile groups are based on the Index of
Multiple Deprivation score for the area of residence. Health outcomes (cases prevented, premature deaths prevented, days of quality-adjusted life, and days of life
gained) are expressed relative to the existing programme. Cases prevented are all cases prevented when following a cohort of 1 million adults aged 40–45 years until
either 80 or 100 years of age. Premature deaths prevented are all-cause deaths prevented before age 75 or 80 years, when following a cohort of 1 million adults aged 40–
45 years until 80 years of age. Additional quality-adjusted life gained and additional life gained are over the 60 years of follow-up, i.e., the remaining lifetime of the
cohort. Estimates of 95% credible intervals (due to parameter uncertainty) are shown in parentheses. The 95% credible intervals are the 2.5th and 97.5th percentile of all
estimates from 100 simulations.
https://doi.org/10.1371/journal.pmed.1002517.t004
The current and potential health benefits of the NHS Health Check programme
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002517 March 6, 2018 16 / 32




Uptake increased by 30%






30% for those at high
risk of CVD±
Increase likelihood of offer of a
health check to previous
nonattenders by 30%
Eligibility and uptake
Eligible for HC at any time (%) 85.1 85.1 85.1 85.1 85.1
Have one or more HCs (%) 83.0 80.0 80.4 80.4 81.4
Mean HCs per head of
population
2.2 1.9 2.0 2.0 2.1
Treatment (proportion of
whole population)
Eligible for HC and any
treatment (%)
81.0 81.0 81.0 81.0 81.0
Attended HC and were eligible
for any treatment when
attending (%)
77.0 73.6 74.1 74.3 75.3
Offered any treatment through
HC (%)
29.8 27 27.3 27.7 28.4
Offered statins through HC (%) 9.6 8.6 8.7 9.2 9.0
Offered antihypertensives
through HC (%)
3.8 3.4 3.4 3.5 3.6
Referred to a weight loss
programme through HC (%)
19.8 17.9 18 18.1 18.9
Referred to smoking cessation
services through HC (%)
1.4 1.2 1.4 1.3 1.3
Treated with statins through HC
(%)
4.9 4.4 4.4 4.7 4.6
Treated with antihypertensives
through HC (%)
2.1 1.8 1.9 1.9 2.0
Attended a weight loss
programme after HC referral (%)
11.4 10.2 10.2 10.3 10.8
Attended smoking cessation
services after HC referral (%)
0.2 0.1 0.2 0.1 0.1
Additional cases prevented by age 80
IHD 149 (60 to 244) 23 (−10 to 65) 42 (2 to 97) 93 (37 to 154) 90 (28 to 154)
Stroke 78 (25 to 146) 12 (−11 to 45) 25 (−10 to 64) 49 (12 to 91) 43 (−5 to 96)
Dementia 29 (−3 to 63) 6 (−9 to 21) 7 (−6 to 28) 2 (−10 to 14) 19 (−4 to 43)
Lung cancer 15 (−12 to 44) 2 (−5 to 13) 16 (−9 to 45) 3 (−9 to 15) 9 (−15 to 30)
Additional people living free of
one of our diseases at age 80
years
200 (82 to 282) 28 (−13 to 66) 58 (19 to 107) 104 (42 to 164) 122 (49 to 191)
Additional cases prevented (by age 100)
IHD 172 (74 to 290) 26 (−16 to 64) 41 (−16 to 94) 125 (50 to 207) 95 (11 to 170)
Stroke 99 (19 to 171) 15 (−18 to 57) 26 (−14 to 75) 72 (15 to 140) 53 (−12 to 118)
Dementia 34 (−22 to 83) 5 (−19 to 28) 5 (−22 to 41) −7 (−36 to 15) 25 (−21 to 73)
Lung cancer 30 (−5 to 76) 3 (−12 to 22) 31 (−3 to 74) 9 (−11 to 35) 19 (−14 to 53)
Additional people living free of
one of our diseases at age 100
years
181 (63 to 308) 26 (−7 to 63) 41 (−8 to 88) 100 (39 to 180) 107 (24 to 191)
Additional deaths prevented (all cause)
<75 years 40 (6 to 76) 6 (−12 to 21) 18 (−10 to 45) 18 (−10 to 46) 25 (−1 to 56)
<80 years 60 (14 to 115) 10 (−9 to 33) 22 (−11 to 55) 30 (0 to 64) 37 (2 to 79)
Additional quality-adjusted life gained over the 60 years of follow-up
Total (QALYs for whole
population)
1720 (781 to 2,760) 268 (−128 to 658) 594 (−27.1 to
1,140)
805 (284 to 1,280) 990 (302 to 1,740)
(Continued)
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parameters contributing most to the uncertainty in the results were the initial adherence to
statin prescription (23% of variance) and the annual dropout rate from statins (15% of vari-
ance), both for analyses estimating the overall contribution of the current NHS Health Check
programme and analyses estimating the benefit of the ‘maximum potential’ scenario.
Sensitivity analyses
Assuming that past attendance predicted future attendance (i.e., those who previously
attended were more likely to attend in the future) resulted in a smaller proportion of the popu-
lation attending for one or more health checks (75% versus 80%), fewer health checks (1.6 ver-
sus 1.9 per head of population), and a marginally smaller overall improvement in population
health (340 versus 390 premature deaths avoided; 1,200 versus 1,400 people living free of the 4
diseases at age 80 years). Under this assumption, the added benefit from a strategy of increas-
ing likelihood of invitation to ‘non-attenders’ was similar (40 deaths versus 40; 130 people free
of 1 of the 4 diseases at age 80 years versus 120; 940 additional QALYs versus 990; and 800





Uptake increased by 30%






30% for those at high
risk of CVD±
Increase likelihood of offer of a
health check to previous
nonattenders by 30%
days per head of population 0.6 (0.3 to 1) 0.1 (0 to 0.2) 0.2 (0 to 0.4) 0.3 (0.1 to 0.5) 0.4 (0.1 to 0.6)
days per eligible person 0.7 (0.3 to 1.2) 0.1 (−0.1 to 0.3) 0.2 (0 to 0.5) 0.3 (0.1 to 0.5) 0.4 (0.1 to 0.7)
days per person screened at least
once
0.8 (0.4, 1.2) 0.1 (−0.1 to 0.3) 0.3 (0 to 0.5) 0.4 (0.1 to 0.6) 0.4 (0.1 to 0.8)
days per health check 0.0 (−0.2 to 0.2) 0.0 (−0.1 to 0.1) 0.0 (−0.1 to 0.1) 0.1 (0 to 0.2) 0.0 (−0.1 to 0.1)
days per head (most deprived
quintile group)
0.7 (−0.3 to 1.7) 0.7 (−0.3 to 1.7) 0.2 (−0.3 to 0.9) 0.4 (−0.2 to 1) 0.3 (−0.4 to 1.2)
days per head (least deprived
quintile group)
0.6 (0 to 1.2) 0.0 (0.0 to 0.0) 0.1 (−0.1 to 0.5) 0.3 (−0.1 to 0.7) 0.4 (−0.2 to 0.9)
Additional life gained over the 60 years of follow-up




242 (−208 to 626) 542 (−88.2 to
1,140)
716 (177 to 1,240) 868 (171 to 1,630)
days per head of population 0.6 (0.2 to 0.9) 0.1 (−0.1 to 0.2) 0.2 (0 to 0.4) 0.3 (0.1 to 0.5) 0.3 (0.1 to 0.6)
days per eligible person 0.6 (0.2 to 1.1) 0.1 (−0.1 to 0.3) 0.2 (0 to 0.5) 0.3 (0.1 to 0.5) 0.4 (0.1 to 0.7)
days per person screened at least
once
0.7 (0.3 to 1.1) 0.1 (−0.1 to 0.3) 0.2 (0 to 0.5) 0.3 (0.1 to 0.6) 0.4 (0.1 to 0.7)
days per health check 0.0 (−0.2 to 0.2) 0.0 (−0.1 to 0.1) 0.0 (−0.1 to 0.1) 0.1 (0.0 to 0.2) 0 (−0.1 to 0.1)
days per head (most deprived
quintile group)
0.6 (−0.5 to 1.7) 0.6 (−0.5 to 1.7) 0.2 (−0.3 to 0.9) 0.4 (−0.4 to 1.0) 0.3 (−0.5 to 1.2)
days per head (least deprived
quintile group)
0.5 (−0.1 to 1.1) 0.0 (0.0 to 0.0) 0.1 (−0.1 to 0.5) 0.2 (−0.1 to 0.7) 0.3 (−0.2 to 0.9)
Abbreviations: CVD, cardiovascular disease; HC, an NHS Health Check; IHD, ischaemic heart disease; QALY, quality-adjusted life year. Deprivation quintile groups are
based on the Index of Multiple Deprivation score for the area of residence. Health outcomes (cases prevented, premature deaths prevented, and days of quality-adjusted
life and days of life gained) are expressed relative to the existing programme. Cases prevented are all cases prevented when following a cohort of 1 million adults aged
40–45 years until either 80 or 100 years of age. Premature deaths prevented are all-cause deaths prevented before age 75 or 80 years, when following a cohort of 1 million
adults aged 40–45 years until 80 years of age. Additional quality-adjusted life gained and additional life gained are over the 60 years of follow-up, i.e., the remaining
lifetime of the cohort. Estimates of 95% credible intervals (due to parameter uncertainty) are shown in parentheses. The 95% credible intervals are the 2.5th and 97.5th
percentile of all estimates from 100 simulations.
± High risk of CVD was defined as QRisk2 > 20%.
https://doi.org/10.1371/journal.pmed.1002517.t005
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Table 6. Effect of increasing treatment on process and outcomes measures of the National Health Service (NHS) health check programme (n = 1,000,000).
2.5-fold increase in the likelihood of starting treatment at assessment amongst eligible patients






Eligible for HC at any time (%) 85.1 85.1 85.1 85.1 85.1
Have one or more HCs (%) 79.6 79.6 79.6 79.6 79.6
Mean HCs per head of population 1.9 1.9 1.9 1.9 1.9
Treatment (proportion of whole population)
Eligible for HC and any treatment (%) 81.0 81.0 81.0 81.0 81.0
Attended HC and were eligible for any treatment
when attending (%)
73.1 73.2 73.2 73.2 73.1
Offered any treatment through HC (%) 34.2 29.4 27.5 39.7 47.4
Offered statins through HC (%) 19.5 8.4 8.4 8.4 19.5
Offered antihypertensives through HC (%) 3.3 8.1 3.3 3.3 8.0
Referred to a weight loss programme through HC (%) 17.6 17.6 17.6 33.3 33.3
Referred to smoking cessation services through HC
(%)
1.2 1.2 2.9 1.2 2.9
Treated with statins through HC through HC (%) 10.3 4.3 4.3 4.3 10.3
Treated with antihypertensives through HC (%) 1.8 4.5 1.8 1.8 4.5
Attended a weight loss programme after HC referral
(%)
9.9 9.9 9.9 21.2 21.2
Attended smoking cessation services after HC referral
(%)
0.1 0.1 0.3 0.1 0.3
Additional cases prevented by age 80
IHD 1,493 (1,084 to
1,910)
67 (28 to 110) 16 (-17 to 48) 14 (0 to 31) 1,589 (1,184 to
2,020)
Stroke 698 (484 to 911) 37 (9 to 67) 10 (−10 to 39) 8 (−4 to 25) 753 (528 to 979)
Dementia 53 (9 to 98) 77 (43 to 123) −3 (−17 to 10) 76 (38 to 123) 202 (132 to 281)
Lung cancer 0 (−5 to 0) 0 (0 to 0) 127 (79 to 182) 0 (0 to 0) 127 (77 to 182)




124 (72 to 179) 108 (58 to 162) 67 (26 to 107) 1,995 (1,550 to
2,440)
Additional cases prevented (by age 100)
IHD 1,825 (1,254 to
2,486)
52 (10 to 94) 1 (−37 to 42) 1 (−20 to 17) 1,878 (1,292 to
2,538)
Stroke 921 (613 to 1,264) 31 (1 to 63) −2 (−31 to 29) 3 (−18 to 23) 952 (647 to 1,309)
Dementia −20 (−84 to 49) 109 (52 to 174) −22 (−44 to 1) 129 (57 to 208) 195 (65 to 316)
Lung cancer 0 (−5 to 0) 0 (0 to 0) 255 (161 to 366) 0 (0 to 0) 255 (159 to 366)




96 (54 to 147) 120 (49 to 176) 66 (24 to 119) 1,787 (1,334 to
2,368)
Additional deaths prevented (all cause) over the 60 years of follow-up
<75 years 265 (191 to 363) 23 (3 to 50) 64 (26 to 106) 12 (0 to 35) 364 (276 to 474)
<80 years 423 (300 to 553) 37 (15 to 75) 79 (30 to 128) 23 (4 to 50) 563 (423 to 731)
Additional quality-adjusted life gained over the 60 years of follow-up




1,730 (840 to 2,660) 782 (324 to 1,330) 15,200 (11,700 to
19,030)
days per head of population 4.2 (3 to 5.5) 0.4 (0.3 to 0.6) 0.6 (0.3 to 1.0) 0.3 (0.1 to 0.5) 5.6 (4.3 to 7)
days per eligible person 4.7 (3.4 to 6.1) 0.5 (0.3 to 0.7) 0.7 (0.4 to 1.1) 0.3 (0.1 to 0.5) 6.3 (4.9 to 7.9)
days per person screened at least once 5.3 (3.8 to 6.8) 0.5 (0.3 to 0.8) 0.8 (0.4 to 1.2) 0.4 (0.1 to 0.6) 7 (5.5 to 8.7)
days per health check 2.2 (1.6 to 2.9) 0.2 (0.1 to 0.3) 0.3 (0.2 to 0.5) 0.2 (0.1 to 0.3) 2.9 (2.3 to 3.6)
days per head (most deprived quintile group) 6.0 (3.8 to 8.6) 0.5 (0.1 to 1) 0.6 (−0.1 to 1.5) 0.4 (0.0 to 0.9) 7.5 (5.1 to 10.4)
days per head (least deprived quintile group) 3.8 (2.5 to 5.6) 0.4 (0.2 to 0.8) 0.5 (−0.1 to 1.1) 0.3 (0.0 to 0.6) 4.9 (3.5 to 6.9)
(Continued)
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Assuming that recent trends in incidence and case fatality for stroke and IHD continue
would reduce the estimate of benefit of the current NHS Health Checks programme by around
half (170 deaths versus 390; 890 people free of 1 of the 4 diseases versus 1,370; 5,700 additional
QALYs versus 10,000; 4,600 additional years of life versus 9,000; Table 7). The estimate of
‘maximum potential’ (relative to present performance) also halved under the same assumption
(400 deaths versus 970; 2,300 people free of 1 of the 4 diseases versus 3,700; 14,000 additional
QALYs versus 27,000; 11,000 additional years of life versus 24,000; Table 7).
Assuming considerable uncertainty in baseline CVD risk (multiplying the QRisk2 score by
a value chosen from a log-normal distribution with 95% quantiles of 0.8 and 1.2) does not




We estimate the current NHS Health Check programme is preventing approximately 300 pre-
mature deaths per year and resulting in 1,000 additional people aged 80 years being free of CVD,
dementia, and lung cancer each year in England. It is increasing quality-adjusted life by around
4 days and life expectancy by around 3 days per person aged 40–45 years. There is potential to
considerably improve the benefits of NHS Health Checks, notably by increasing uptake of treat-
ments, increasing attendance, and extending the programme to include those with diagnosed
hypertension. In keeping with the benefits of the current programme, most of these modifica-
tions are associated with an improvement in health equity and compression of morbidity.
Strengths and limitations
Our work has several strengths. We have estimated the additional benefit of the NHS Health
Check programme, over and above routine care, by using data that reflect changes in risk
Table 6. (Continued)
2.5-fold increase in the likelihood of starting treatment at assessment amongst eligible patients





Additional life gained over the 60 years of follow-up
Total (years for whole population) 9,970 (7,080 to
13,400)
913 (512 to 1,420) 1,750 (855 to 2,780) 632 (229 to 1,120) 13,300 (10,300 to
16,800)
days per head of population 3.6 (2.6 to 4.9) 0.3 (0.2 to 0.5) 0.6 (0.3 to 1.0) 0.2 (0.1 to 0.4) 4.8 (3.8 to 6.1)
days per eligible person 4.1 (2.9 to 5.4) 0.4 (0.2 to 0.6) 0.7 (0.4 to 1.1) 0.3 (0.1 to 0.4) 5.5 (4.3 to 6.9)
days per person screened at least once 4.6 (3.3 to 6.0) 0.4 (0.2 to 0.7) 0.8 (0.4 to 1.3) 0.3 (0.1 to 0.5) 6.1 (4.8 to 7.6)
days per health check 1.9 (1.4 to 2.5) 0.2 (0.1 to 0.3) 0.3 (0.2 to 0.5) 0.1 (0.0 to 0.2) 2.6 (2.0 to 3.2)
days per head (most deprived quintile group) 5.2 (3.3 to 7.9) 0.4 (0.1 to 0.9) 0.6 (−0.2 to 1.5) 0.3 (0.0 to 0.8) 6.5 (4.2 to 9.6)
days per head (least deprived quintile group) 3.3 (2.1 to 5.0) 0.3 (0.1 to 0.7) 0.5 (−0.1 to 1.1) 0.2 (0 to 0.5) 4.3 (2.8 to 6.1)
Abbreviations: HC, an NHS Health Check; IHD, ischaemic heart disease; QALY, quality-adjusted life year. Deprivation quintile groups are based on the Index of
Multiple Deprivation score for the area of residence. Health outcomes (cases prevented, premature deaths prevented, days of quality-adjusted life, and days of life
gained) are expressed relative to the existing programme. Cases prevented are all cases prevented when following a cohort of 1 million adults aged 40–45 years until
either 80 or 100 years of age. Premature deaths prevented are all-cause deaths prevented before age 75 or 80 years, when following a cohort of 1 million adults aged 40–
45 years until 80 years of age. Additional quality-adjusted life gained and additional life gained are over the 60 years of follow-up, i.e., the remaining lifetime of the
cohort. Estimates of 95% credible intervals (due to parameter uncertainty) are shown in parentheses. The 95% credible intervals are the 2.5th and 97.5th percentile of all
estimates from 100 simulations.
https://doi.org/10.1371/journal.pmed.1002517.t006
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Fig 2. Health equity plot showing the effect of modifications to the existing programme on overall effectiveness
(health gain) and on health equity.
https://doi.org/10.1371/journal.pmed.1002517.g002
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Table 7. Sensitivity analysis showing the impact of a reduction in cardiovascular disease (CVD) risk (incidence and case fatality) on the estimate of benefits attribut-
able to the National Health Service (NHS) health check programme.
Current NHS Health Check programme
(compared to no programme)
‘Maximum potential’ scenario (compared to
current programme)
No decline in CVD
risk
Decline in CVD risk No decline in CVD risk Decline in CVD risk
Additional cases prevented by age 80 (per million)
IHD 1,089 (817 to 1,367) 592 (465 to 794) 2,802 (2,236 to 3,459) 1,533 (1,263 to 1,915)
Stroke 525 (414 to 671) 269 (181 to 371) 1,335 (1,063 to 1,656) 704 (531 to 933)
Dementia 135 (72 to 190) 126 (53 to 208) 320 (220 to 462) 299 (155 to 447)
Lung cancer 90 (36 to 147) 94 (44 to 151) 207 (133 to 293) 221 (145 to 310)
Additional people living free of one of our diseases at age 80
years
1,371 (1,101 to 1,685) 886 (697 to 1,122) 3,562 (2,903 to 4,253) 2,286 (1,891 to 2,716)
Additional cases prevented by age 100 (per million)
IHD 1,296 (898 to 1,730) 811 (580 to 1,129) 3,837 (2,833 to 4,962) 2,407 (1,840 to 3,009)
Stroke 679 (494 to 958) 400 (269 to 564) 1,993 (1,518 to 2,565) 1,215 (904 to 1,619)
Dementia 125 (32 to 222) 267 (141 to 393) 235 (75 to 384) 625 (421 to 853)
Lung cancer 175 (103 to 259) 186 (113 to 281) 435 (311 to 567) 469 (331 to 596)
Additional people living free of one of our diseases at age 100
years
1,235 (956 to 1,566) 1,044 (784 to 1,379) 3,654 (2,842 to 4,591) 3,007 (2,400 to 3,721)
Additional premature deaths prevented (per million)
<75 years 246 (182 to 331) 101 (47 to 164) 544 (424 to 713) 211 (137 to 294)
<80 years 386 (291 to 499) 167 (82 to 253) 967 (777 to 1,215) 402 (287 to 516)
Additional quality-adjusted life gained over the 60 years of follow-up








days per head of population 3.8 (3.0 to 4.7) 2.1 (1.5 to 2.8) 10.0 (8.2 to 12.2) 5.2 (4.3 to 6.4)
days per eligible person 4.3 (3.4 to 5.4) 2.5 (1.8 to 3.3) 10.6 (8.7 to 12.9) 5.7 (4.7 to 6.9)
days per person screened at least once 4.7 (3.8 to 6.0) 2.7 (2.1 to 3.5) 11.3 (9.3 to 13.7) 6.0 (5.0 to 7.3)
days per health check 2.0 (1.6 to 2.5) 1.1 (0.8 to 1.4) 3.0 (2.5 to 3.8) 1.5 (1.2 to 1.9)
days per head (most deprived quintile group) 5.1 (3.4 to 7.1) 2.7 (1.2 to 4.2) 12.9 (9.0 to 16.7) 6.9 (4.7 to 9.7)
days per head (least deprived quintile group) 3.3 (2.1 to 4.5) 1.7 (0.7 to 2.8) 9.0 (6.6 to 11.3) 4.5 (2.7 to 6.4)
Additional life gained over the 60 years of follow-up




11,500 (9,360 to 14,200)
days per head of population 3.3 (2.5 to 4.1) 1.7 (1.1 to 2.4) 8.8 (7.1 to 10.7) 4.2 (3.4 to 5.2)
days per eligible person 3.7 (2.8 to 4.8) 2.0 (1.4 to 2.7) 9.3 (7.6 to 11.3) 4.6 (3.7 to 5.6)
days per person screened at least once 4.1 (3.2 to 5.2) 2.2 (1.6 to 2.9) 9.9 (8.1 to 12) 4.8 (3.9 to 5.9)
days per health check 1.7 (1.4 to 2.2) 0.9 (0.6 to 1.2) 2.7 (2.1 to 3.3) 1.2 (0.9 to 1.5)
days per head (most deprived quintile group) 4.4 (2.7 to 6.5) 2.1 (0.7 to 3.6) 11.3 (7.6 to 15.3) 5.5 (3.3 to 7.8)
days per head (least deprived quintile group) 2.8 (1.7 to 4.0) 1.4 (0.4 to 2.5) 7.8 (5.5 to 9.9) 3.6 (1.9 to 5.5)
Abbreviations: HC, an NHS Health Check; IHD, ischaemic heart disease; QALY, quality-adjusted life year. Deprivation quintile groups are based on the Index of
Multiple Deprivation score for the area of residence. Health outcomes (cases prevented, premature deaths prevented, days of quality-adjusted life, and days of life
gained) are expressed relative to the existing programme. Cases prevented are all cases prevented when following a cohort of 1 million adults aged 40–45 years until
either 80 or 100 years of age. Premature deaths prevented are all-cause deaths prevented before age 75 or 80 years, when following a cohort of 1 million adults aged 40–
45 years until 80 years of age. Additional quality-adjusted life gained and additional life gained are over the 60 years of follow-up, i.e., the remaining lifetime of the
cohort. Estimates of 95% credible intervals (due to parameter uncertainty) are shown in parentheses. The 95% credible intervals are the 2.5th and 97.5th percentile of all
estimates from 100 simulations. The ‘maximum potential’ scenario models the effect of simultaneously widening eligibility to include those with a diagnosis of
hypertension, increasing attendance by 30% for everyone and increasing all treatments by 2.5-fold.
https://doi.org/10.1371/journal.pmed.1002517.t007
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factors over time considering changes due to routine healthcare and by using estimates of
additional treatments attributable to an NHS Health Check. By comparing NHS Health
Checks with a counterfactual situation of no NHS Health Checks on the same population, we
have eliminated the selection bias (i.e., healthy people who are concerned about their health
choosing to attend a health check) that may affect observational studies of the programme. We
have also made allowance for nonadherence and relapse of treatment. As a result, the model
effectively simulates the impact of treatment decisions dissipating over time, resulting in a
smaller estimate of benefit compared to approaches assuming fixed adherence over time. The
microsimulation approach gives substantial flexibility, allowing exploration of different sce-
narios, testing of assumptions, and description of outcomes by subgroup.
By modelling differences in uptake by deprivation and disease incidence by deprivation
(due to differences in risk factor prevalence and using QRisk2 score, which includes depriva-
tion and ethnicity as predictive factors), we have been able to model health impacts by depriva-
tion. However, we have not made allowance for likely differences in survival (case fatality) by
deprivation, which may have led to an underestimation of the programme’s impact on reduc-
ing health inequalities [70,71]. We have also assumed the same level of adherence to treatment
by deprivation. Different levels of adherence by deprivation might also affect the programme’s
impact on inequalities.
We have represented uncertainty around multiple input parameters. Nonetheless, as with
all models, there are parts for which we could find limited data (e.g., likelihood of repeat atten-
dance for an NHS Health Check, attendance at a weight management programme after refer-
ral, and long-term compliance with medication), and the measured ‘parametric’ uncertainty
may not capture the ‘true’ uncertainty in some of the parameters (e.g., disutility weights). We
have not made any allowance for migration, although we note that inward migration is less
common in the age group (over 40 years) that we studied [72].
We have also assumed that the present background incidence of disease continues and that
no major new treatments will be developed. Different assumptions about future disease inci-
dence or risk factors would alter the estimates of overall health benefit and might affect the
overall estimate of relative benefit of the different scenarios. It is noticeable that the estimate of
overall benefit falls by as much as half if the present downward trend in CVD continues for
another 20 years. This underscores the challenges in making forecasts about the benefits in
health attributable to the programme in the long term.
There are also differences in disease incidence and variation in programme delivery
between local authorities, which may result in different estimates of absolute benefit, at a local
level, to those presented here. Whilst dementia risk is modifiable [29,41], there is no trial evi-
dence to demonstrate the effects of lipid-lowering therapy, weight loss, or smoking on demen-
tia incidence, and consequently, the effects on dementia should be treated with caution.
There are aspects of the programme we have not considered. We have not estimated costs,
nor have we considered harms of treatments. Notably, we have not considered the additional
risk of type 2 diabetes attributable to statins, which might influence the modelled benefits of
statins used in primary prevention [73,74]. Other side effects are likely to be short-lived, and
thus, their overall contribution to (lifelong) disutility would be small, and allowance has been
made for patients not starting and discontinuing medication (which may be a response to side
effects and thus limit the duration of side effects). Elements of the programme we have not
modelled include brief interventions around alcohol, benefits from early diagnosis (e.g.,
chronic kidney disease and type 2 diabetes). With the exception of lung cancer, other (noncar-
diovascular) health benefits (e.g., weight loss on cancer and smoking on other cancers and
chronic obstructive pulmonary disease [COPD]) have not been modelled. In some settings,
the largest contributor to QALY benefit from smoking cessation is through reduction in
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COPD [75]. Given this and the exclusion of other health outcomes, our estimate of health gain
is likely to underestimate the overall health gain from the programme. We focused on the car-
diovascular elements of the NHS Health Check because this was the original focus of the pro-
gramme, because of the large burden of disease attributable to CVD, and because of the well-
developed evidence base describing treatment uptake and effectiveness.
We note that the cardiovascular benefits attributable to weight loss interventions (Table 6)
are less than for other treatments, despite a large number of referrals to weight management.
This is in part because it was assumed that any weight loss was fully regained over a 5-year
period. It may in part reflect the cardiovascular benefits of weight being modelled through
QRisk2 score, which includes BMI. We did not additionally explicitly model the impact of
BMI on other risk factors (e.g., cholesterol and blood pressure), as changes in these risk factors
through changes in BMI have been implicitly modelled through the matching process that
models change in risk factors over time (see Section 2.1 in S1 Text). Nonetheless, this approach
may have underestimated the benefits of weight loss on CVD.
We have primarily considered benefits at the population level, which are different to bene-
fits at the individual level. Stopping smoking is highly beneficial for health at an individual
level, but that component of the programme is currently delivering limited population benefit
because few individuals are being referred to smoking cessation services (through the NHS
Health Check programme). This may reflect national declines in demand for smoking cessa-
tion services, in part due to declines in smoking prevalence and in part due to the availability
of e-cigarettes. The individual benefit for an individual who is referred to smoking cessation
services and who quits will be substantial. Whilst we have tried to choose scenarios based on
what may be realistically or ideally attainable, we do not know what is possible. We note others
have commented on the suboptimal uptake of treatments amongst people attending a health
check [14]. Low uptake of treatments may reflect variation in quality of care but may be due to
clinical factors (e.g., patient choice, side effects, or contraindications).[76]
This work concerns one aspect of secondary prevention of CVD. In terms of reducing mor-
bidity and mortality from CVD other aspects of prevention, such as population-level
approaches (e.g., cigarette taxation and reformulation to reduce salt) [75,77,78], and aspects of
clinical care (e.g., management of acute coronary syndromes) are valuable. This work does not
attempt to consider the relative contributions of these different elements, which others have
done [15]. In practice, countries are likely to adopt a spectrum of approaches from primary
prevention, at the population level, to the delivery of high-quality clinical care to individuals to
reduce the burden of CVD [79].
Model validation
There are different views on the appropriateness and meaning of the concept of validity in
model development. We take the position that validity needs to be considered in the context of
use. It is not possible for a model to be universally valid. Models can be used to answer multiple
questions, and validity should be considered specifically for each question. Validation through
comparing a model’s findings with empirical research is usually only partially possible, as
models are typically used to answer questions that no single empirical study can answer. Other
factors need to be considered when deciding whether a model is ‘valid’ or robust. We think
our model is robust because of (1) the use of good data sources, e.g., national data on disease
epidemiology, published data on programme performance, and estimates of treatment efficacy
from trials; (2) the steps taken during model development, e.g., calibration and use of expert
advice; (3) the comparisons of some model outputs with mortality data, i.e., effectively validat-
ing the population health module; (4) extensive stochastic uncertainty analysis and sensitivity
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analysis; and (5) comparisons with other modelling studies (described below). The uncertainty
and sensitivity analyses suggest that the pattern of findings and the estimates of order of mag-
nitude are broadly similar under a range of different assumptions for the comparisons of most
interest to us. Substantial changes in CVD risk, now or in the future, and statin adherence
have been identified as factors most likely to have a marked impact on estimate of benefit.
Comparison to other work
We are not aware of any other work that has sought to estimate the impact of making changes
to the NHS Health Check programme. We note that the original modelling work, undertaken
by the Department of Health, suggested that 40 was the optimal age to start screening [80], and
consistent with this, we found a small health loss associated with increasing the starting age to
50 years.
The original modelling undertaken by the Department of Health estimated that the pro-
gramme could prevent 1,600 heart attacks and strokes and at least 650 premature deaths each
year [81]. Kypridemos et al. estimated that a ‘vascular check programme’ in the UK might pre-
vent approximately 1,000 nonfatal and 200 fatal cases of CVD annually [15]. While there are
important differences between the models (e.g., effectiveness of statins and trends in CVD
incidence), we note that despite this, these estimates and our own (1,700 events, of which 1,400
are attributable to CVD, and 300 premature deaths prevented per annum) are relatively simi-
lar. Our estimates for the increase in QALYs (3.8 days per head of population) are of a similar
order of magnitude but are less than half of the estimates of a ‘health check’ programme (8.6
days per head of population) when following a population for 30 years using the Archimedes
model, which has been validated for diabetes treatments [16,82]. While we cannot be sure how
‘valid’ these other model estimates are, if they are ‘valid’, these comparisons provide some reas-
surance concerning the validity of our model’s output.
Our work can also be compared to observational reports of the current programme. One
study estimated the health benefits for those who attend for a health check compared to a
matched control group who do not attend [83]. The paper reported similar levels of treatment
to those that we modelled and reported changes in cardiovascular risk factors (e.g., 2.5 mmHg
reduction in blood pressure) for attenders relative to nonattenders. We note that these differ-
ences are relatively large (our respective estimates being 0.07 mmHg for those who attend for a
health check), at a population-level, and would result in much greater health improvements
than those that we estimated. These discrepancies in health outcomes may be explained by
residual confounding of the observational data (i.e., those who attend for a health check are
healthier than those who do not) or may suggest other pathways through which the health
check may be influencing cardiovascular risk, such as stimulating participants to adopt health-
ier habits (e.g., being physically active or eating a healthier diet).
Comparisons with other population-level interventions should be interpreted cautiously, as
methods may vary and the nature and scale of the interventions can be very different. Struc-
tural interventions (e.g., taxing unhealthy foods, 2,300 CVD deaths averted; salt reformulation,
6,000 CVD deaths averted per annum) may have a greater impact on CVD [78,84]. Such inter-
ventions can be politically difficult to implement, and individual interventions may be better
seen as a complement to structural approaches [79]. Comparisons with screening programmes
may be instructive, as the programme shares some characteristics with screening programmes.
Breast cancer screening in the UK is estimated to increase life expectancy by 6.9 days and
QALYs by 2.0 days per eligible women [85], whilst bowel cancer screening is estimated to
increase life expectancy by 4.6 to 9.6 days (depending on the screening model adopted) and
QALYs by 3.8 to 10.2 days per eligible person [86]. Currently, the NHS Health Check
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programme is performing at the lower end of these estimates, although our work suggests it
has the potential to exceed the benefits of these screening programmes.
Interpretation and implications
Broadly, our work suggests the programme is contributing to benefits in population health
and is also serving to reduce health inequalities. As the gain in time lived in full health is
greater than the increase in survival, the programme is adding more good quality life years
than it is adding years to life (i.e., it is compressing morbidity).
We have presented 2 contrasting metrics of benefit, one based around events avoided and a
second based on increase in life expectancy (including QALYs). QALYs are important for
making comparisons with other health interventions and making judgements about cost-effec-
tiveness. We have presented numbers for the population, as a whole, and per head of popula-
tion. The latter is standardised for the population size and is a common metric used to
describe the benefit of other similar programmes, i.e., screening programmes. However, the
mean benefit per person can be misleading, as the benefits are not evenly distributed. The
events avoided may be a better way to communicate how the programme may offer a substan-
tial benefit (prevention of major disease or premature death) for a small proportion of the
population.
If the programme were optimised, the health benefits of the programme could be even
greater. Our work suggests a number of approaches that might enable this. Increasing the
uptake of treatments, principally statins, through the programme may be a more important
strategy to increase the health benefits of the programme. This appears to be more important
than increasing programme attendance, which has been a focus of efforts to improve the pro-
gramme to date. It might be a more efficient use of resources to ensure the programme is opti-
mally managing patients before seeking to increase attendance.
The benefits of statins offered through the programme were particularly pronounced.
Given the recent recommendations from the UK’s National Institute for Health and Care
Excellence (NICE) to lower the threshold for initiating statin therapy for primary prevention
[87], it seems likely that there will be scope to increase statin therapy. Other interventions
are estimated to have a smaller impact. Nonetheless, there is scope for their impact to be
greater. For example, smoking cessation is highly beneficial but had a very low uptake [88]; the
benefit of this component of the programme could be greater if more smokers were referred.
It seems likely that weight loss interventions would be more beneficial if the weight loss was
maintained. Overall, there may be a need for quality assurance around elements of the pro-
gramme, as there are in screening programmes, to enable the programme to maximise its
potential.
National data suggest some targeting of high-risk groups (e.g., based on deprivation or eth-
nicity) already occurs [15,44], and this approach has appeared to be successful in reducing
health inequalities. Now that the programme is established, targeting those who did not attend
in the previous 5-year cycle would also appear to be a sensible strategy, as a complement to
existing targeting strategies. Given the relatively large incremental gain for extending the pro-
gramme to include those with an existing diagnosis of hypertension, this change in eligibility
criteria merits further exploration.
Given that we have not considered costs, it would be inappropriate to draw conclusions
about the overall cost-effectiveness of the overall programme or the marginal cost-effectiveness
of the change scenarios we explore. However, we note our estimates of benefits in terms of
new cases of CVD prevented are similar to the estimates from the original modelling prior to
programme’s introduction, which suggested that the programme was cost-effective [80].
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Future research
We have primarily considered health benefits. Whilst a detailed assessment of health impact is
important in making decisions about the NHS Health Check programme, future work should
integrate cost data and undertake a cost-effectiveness or cost-utility analysis, which will pro-
vide a stronger basis for decision making. Future modelling work may want to consider other
scenarios around changes in delivery, e.g., targeting known smokers or opportunistic health
checks in primary care. Our scenarios on the potential increase in uptake of different treat-
ment for statins are based on what is being achieved in one well-performing area. However,
there is considerable uncertainty about what could be achieved (at scale) and how much it
would cost. What our study does provide is an indication of how much additional health bene-
fit could be realised if these scenarios were achieved. Further work might want to explore why
referral and treatment rates are apparently low and how these rates might be increased. As
data on the operation of the programme improve, researchers will be better able to estimate
the current and potential future health impacts. Programme data should also allow direct
observation of benefit (e.g., change in blood pressure), although in the absence of randomised
controlled trials, issues concerning selection bias will limit the use of such comparisons. How-
ever, observational studies may lack power to detect the differences in ‘hard’ health outcomes
at a population level that we report in this paper. Modelling will continue to be necessary to
investigate longer-term outcomes of the current programme and to address ‘what if’ questions
about the possible benefits of making changes to the programme. Other similar models do
exist [15,16,73]. Formal comparisons between models may serve as a form of validation and
means to identify the respective strengths and weaknesses of the different models.
Summary
Our work suggests that the current NHS Health Check programme is contributing to improve-
ments in population health, a narrowing of health inequalities, and compressing morbidity.
There appears to be considerable scope to improve the health benefit of the programme, par-
ticularly by ensuring those who are assessed and eligible for treatment receive appropriate
treatment. Focusing on inviting previous nonattenders and widening the eligibility criteria to
include those with an existing diagnosis of hypertension could also make a valuable contribu-
tion to increasing the health benefits of the programme.
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